Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Controlled Study Aiming to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain.

NCT04704453 is registered in ClinicalTrials.gov with Institut Claudius Regaud as lead sponsor.

NCT NCT04704453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04704453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Controlled Study Aiming to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain.
Lead sponsor
Institut Claudius Regaud
Phase
Phase 2
Overall status
Completed
Start date
April 28, 2021
Completion date
April 28, 2025
Enrollment
13 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer